This Article Full Text Full Text (PDF) All Versions of this Article: 114/24/2644    most recent CIRCULATIONAHA.106.637025v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ashley, E. A. Articles by Quertermous, T. Search for Related Content PubMed PubMed Citation Articles by Ashley, E. A. Articles by Quertermous, T. Pubmed/NCBI databases Substance via MeSH Related Collections Restenosis Functional genomics Genomics Smooth muscle proliferation and differentiation Catheter-based coronary interventions: stents

(Circulation. 2006;114:2644-2654.)
© 2006 American Heart Association, Inc.

Interventional Cardiology

Network Analysis of Human In-Stent Restenosis

Euan A. Ashley, MRCP, DPhil; Rossella Ferrara, MD; Jennifer Y. King, BS; Aditya Vailaya, PhD; Allan Kuchinsky, MS; Xuanmin He, MD, PhD; Blake Byers, BS; Ulrich Gerckens, MD; Stefan Oblin, MD; Anya Tsalenko, PhD; Angela Soito, BS, JD; Joshua M. Spin, MD, PhD; Raymond Tabibiazar, MD; Andrew J. Connolly, MD; John B. Simpson, MD, PhD; Eberhard Grube, MD; Thomas Quertermous, MD

From the Division of Cardiovascular Medicine, Falk CVRC, Stanford University, Stanford, Calif (E.A.A., R.F., J.Y.K., B.B., J.M.S., A.J.C., T.Q.); HELIOS Heart Center Siegburg, Siegburg, Germany (U.G., S.O., E.G.); Agilent Laboratories, Palo Alto, Calif (A.V., A.K., A.T.); Foxhollow Technologies, Redwood City, Calif (X.H., A.S., J.B.S.); and Aviir Inc, Palo Alto, Calif (R.T.).

Correspondence to Dr E.A. Ashley, Stanford University, 300 Pasteur Dr, Stanford, CA 94305 (e-mail euan{at}stanford.edu ); Dr E. Grube, Stanford University, 300 Pasteur Dr, Stanford, CA 94305 (e-mail grubee@aol.com); or Dr T. Quertermous, Stanford University, 300 Pasteur Dr, Stanford, CA 94305 (e-mail tomq1@stanford.edu).

Received April 29, 2006; revision received September 21, 2006; accepted September 22, 2006.

Background— Recent successes in the treatment of in-stent restenosis (ISR) by drug-eluting stents belie the challenges still faced in certain lesions and patient groups. We analyzed human coronary atheroma in de novo and restenotic disease to identify targets of therapy that might avoid these limitations.

Methods and Results— We recruited 89 patients who underwent coronary atherectomy for de novo atherosclerosis (n=55) or in-stent restenosis (ISR) of a bare metal stent (n=34). Samples were fixed for histology, and gene expression was assessed with a dual-dye 22 000 oligonucleotide microarray. Histological analysis revealed significantly greater cellularity and significantly fewer inflammatory infiltrates and lipid pools in the ISR group. Gene ontology analysis demonstrated the prominence of cell proliferation programs in ISR and inflammation/immune programs in de novo restenosis. Network analysis, which combines semantic mining of the published literature with the expression signature of ISR, revealed gene expression modules suggested as candidates for selective inhibition of restenotic disease. Two modules are presented in more detail, the procollagen type 1 2 gene and the ADAM17/tumor necrosis factor- converting enzyme gene. We tested our contention that this method is capable of identifying successful targets of therapy by comparing mean significance scores for networks generated from subsets of the published literature containing the terms "sirolimus" or "paclitaxel." In addition, we generated 2 large networks with sirolimus and paclitaxel at their centers. Both analyses revealed higher mean values for sirolimus, suggesting that this agent has a broader suppressive action against ISR than paclitaxel.

Conclusions— Comprehensive histological and gene network analysis of human ISR reveals potential targets for directed abrogation of restenotic disease and recapitulates the results of clinical trials of existing agents.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				A. S. Plump and P. Y. Lum Genomics and cardiovascular drug development. J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1089 - 1100. [Abstract] [Full Text] [PDF]

				E. A. Ashley, J. M. Spin, R. Tabibiazar, and T. Quertermous Frontiers in Nephrology: Genomic Approaches to Understanding the Molecular Basis of Atherosclerosis J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2853 - 2862. [Abstract] [Full Text] [PDF]

				R. C. Becker Emerging Paradigms, Platforms, and Unifying Themes in Biomarker Science J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1777 - 1780. [Full Text] [PDF]